Bloomington, Ind. – At this year’s Vascular Interventional Advances (VIVA) conference, Dr. Anthony Comerota presented data on the Zilver® Vena™ Venous Self-Expanding Stent that demonstrates durable patency and symptom relief in patients over an extended period of time.1
Zilver Vena is a self-expanding stent designed to meet the needs of patients suffering from symptomatic iliofemoral venous outflow obstruction.1 When implanted in a patient, Zilver Vena expands to restore venous flow. 1
At the VIVA conference, the data presented were gathered from the Zilver Vena VIVO US Study. The study involved 243 patients who were reflective of a real-world population, including representations of acute and chronic disease as well as thrombotic and non-thrombotic lesions.1 Key highlights of the study include:
- Zilver Vena is effective in treating venous obstruction with 89.9% patency and 95% freedom from clinically driven reintervention at 1 year post-procedure.1
- Zilver Vena is safe and durable with a 96.7% freedom from major adverse events at 30 days and 0 stent fractures at 1 year post-procedure.1
- Patients treated in the VIVO-US study were consistent with those in previous literature reports and reflective of a real-world population which included acute and chronic disease, and thrombotic and non-thrombotic lesions with 32.5% of stent extension beyond the inguinal ligament into the femoral and common femoral vein.1
- Patients treated with Zilver Vena improved clinically with a mean drop in VCSS of 4.2 points.1
“We are proud to share the Zilver VIVO data at the VIVA conference,” said Mark Breedlove, vice president of Cook Medical’s Vascular division. “We know that venous disease is a serious and complex condition. These data are a milestone in our commitment to driving venous therapies.”
For more information, visit the Zilver Vena product page here.
Dr. Comerota is a paid consultant of Cook Medical.
Please see product risk information in the IFU at cookmedical.eu.
About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: our patients, our employees, and our communities. Find out more at CookMedical.eu, and for the latest news, follow us on Twitter, Facebook and LinkedIn.
1 VIVO clinical study. ClinicalTrials.gov Web site. https://clinicaltrials.gov/ct2/show/results/NCT01970007. Published October 25, 2013. Updated April 08, 2021. Accessed April 08, 2021.